Elanco Animal Health (NYSE:ELAN) Announces Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Elanco Animal Health (NYSE:ELAN) posted its quarterly earnings results on Thursday. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.01, Briefing.com reports. The business had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $1.04 billion. Elanco Animal Health had a positive return on equity of 7.29% and a negative net margin of 27.94%. Elanco Animal Health’s quarterly revenue was down 3.6% on a year-over-year basis. During the same quarter last year, the company posted $0.18 earnings per share.

Elanco Animal Health Stock Performance

ELAN opened at $14.07 on Friday. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.93 and a quick ratio of 1.75. The company has a market capitalization of $6.96 billion, a PE ratio of 35.18, a price-to-earnings-growth ratio of 1.34 and a beta of 1.41. The business has a fifty day simple moving average of $13.93 and a 200 day simple moving average of $14.73. Elanco Animal Health has a 1 year low of $10.19 and a 1 year high of $18.80.

Insider Transactions at Elanco Animal Health

In other Elanco Animal Health news, Director Michael J. Harrington purchased 3,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 22nd. The shares were acquired at an average cost of $14.85 per share, for a total transaction of $51,975.00. Following the completion of the purchase, the director now owns 81,094 shares of the company’s stock, valued at approximately $1,204,245.90. The trade was a 0.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Michael J. Harrington purchased 3,500 shares of the business’s stock in a transaction that occurred on Thursday, August 22nd. The stock was acquired at an average cost of $14.85 per share, for a total transaction of $51,975.00. Following the completion of the purchase, the director now owns 81,094 shares in the company, valued at approximately $1,204,245.90. This represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jeffrey N. Simmons purchased 100,000 shares of Elanco Animal Health stock in a transaction that occurred on Monday, August 12th. The shares were bought at an average cost of $13.01 per share, for a total transaction of $1,301,000.00. Following the transaction, the chief executive officer now directly owns 145,000 shares of the company’s stock, valued at $1,886,450. This represents a 200.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 0.57% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on ELAN shares. Stifel Nicolaus reiterated a “buy” rating and set a $20.00 target price on shares of Elanco Animal Health in a research note on Thursday, September 19th. Morgan Stanley cut shares of Elanco Animal Health from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $17.00 to $15.00 in a research report on Thursday, September 19th. Finally, Barclays upped their price objective on shares of Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a report on Friday. One analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $17.14.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.